A Study Evaluating The Combination of Immunotherapy With Radiotherapy in Non-Small Cell Lung Cancer

Part of paid clinical trials in Chicago, Illinois.

Sponsor
University of Chicago
Study ID
NCT07603856
Phase
PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Investigator Choice Immunotherapy (for example: pembrolizumab, cemiplimab, durvalumab, ipilimumab plus nivolumab) — DRUG
    Participant will receive an FDA approved immunotherapy according to usual routine practice.
  • Investigator Choice Chemotherapy (for example docetaxel with or without ramucirumab, gemcitabine, or other National Comprehensive Cancer Network (NCCN)-recommended treatments) — DRUG
    Description something along the lines of Participant will receive an FDA approved chemotherapy according to usual routine practice.
  • Ablative Hypofractionated Radiotherapy — RADIATION
    Participant will receive radiotherapy according to usual routine practice.

Study Details

Current clinical trials testing the combination of immunotherapy with radiotherapy.

Key Dates

Start date
Dec 12, 2026
Status verified
May 2026
Primary completion
Jun 25, 2030
Completion
Jun 25, 2030

Study Design

Enrollment
39 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Radiotherapy (RT) + Immunotherapy
    Participants will receive standard immunotherapy of investigator's choice in combination with radiation treatment.
  • Active Comparator: Standard Chemotherapy (Investigator's Choice")
    Participants will receive standard chemotherapy of investigator's choice.

Primary Outcome Measure

Progression-free survival (PFS) [ Time Frame: 48 months ]

Locations (1)

FacilityCityStateZIPSite coordinators
o University of Chicago Medicine Comprehensive Cancer CenterChicagoIllinois60637-

Find similar trials in Chicago, IL

By condition
Lung cancer
By specialty
OncologyLung oncologyLung disease
By research site
o University of Chicago Medicine Comprehensive Cancer Center· Chicago, IL

Related Studies